ProciseDx™ Announces CE Mark for Point of Care Inflammatory Marker AssayHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 15 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)ProciseDx™ Announces CE Mark for Point of Care Inflammatory Marker AssayPR NewswireJanuary 10, 2020ReblogShareTweetShareSAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- ProciseDx today announced the attainment of CE mark for its Procise CRP assay (C reactive protein) which is the first of its family of gastrointestinal markers. This follows the announcement of CE mark for the ProciseDx instrument in September 2019.View photosThe ProciseDx instrument is about the size of a shoe box and can provide diagnostics results in as little as 2 minutes from a finger prick drop of blood.MoreProciseDx is an in vitro diagnostics company focused on the development of a broad portfolio of rapid diagnostic tests for the physician's office. Today's announcement advances the company's strategy of developing and commercializing 2 to 5-minute point-of-care tests that are easy, immediate and accurate. These tests use finger prick blood or stool samples to quantify biomarkers for drug levels, metabolic syndrome, diabetes, celiac and inflammatory diseases."We are very excited to have the opportunity to build a diagnostics company with revolutionary and disruptive technology.  We are launching our platform and gastrointestinal assay portfolio in Europe later this year," said Peter Westlake, President of ProciseDx.  "We're also completing our first clinical trials in the US and plan an FDA 510k submission for the instrument system and Procise CRP in Q1 2020.  With our latest funding round opening in Q1, this will be a big year for ProciseDx."About ProciseDx Inc.ProciseDx is a diagnostics company committed to the development and commercialization of a broad portfolio of point-of care diagnostic tests for use in physician offices, urgent care and retail clinics. ProciseDx has 24 employees, 10,000 sq ft of office, laboratory and manufacturing space and is ISO13485 certified.ProciseDx is headquartered in San Diego. For more information about ProciseDx, please visit us at www.procisediagnostics.com.Media Contact:Peter Westlake619.821.0660232212@email4pr.com View photosProciseDxMoreCisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/procisedx-announces-ce-mark-for-point-of-care-inflammatory-marker-assay-300984724.htmlSOURCE ProciseDxReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoWhat the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoLoan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceU.S. airlines suspend flights over coronavirus fearsYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance